Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a member of a family of glycoprotein hormones that stimulate the proliferation and differentiation of hemopoietic cells in vitro and in vivo. We now report that human GM-CSF can also stimulate the proliferation of two osteogenic sarcoma cell lines, a breast carcinoma cell line, a simian virus 40-transformed marrow stromal cell line, and normal marrow fibroblast precursors. These findings suggest a more general regulatory function of GM-CSF on nonhemopoietic cell types than previously anticipated. They also raise the possibility of adverse side effects of GM-CSF therapy in
Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein first identified by its presence in crude preparations of conditioned medium that stimulate immature hemopoietic cells to proliferate and differentiate in vitro into mature granulocytes and macrophages (reviewed in ref. 1) . Both murine and human GM-CSF have been purified to homogeneity (2, 3) and their genes cloned and expressed (4) (5) (6) . The resultant availability of large amounts of purified recombinant protein has allowed a wider range of primitive (7, 8) and fully differentiated (3, 9) cell types within the hemopoietic system to be recognized as directly GM-CSF responsive than was initially appreciated. The ability of GM-CSF to markedly stimulate the production (and function) of granulocytes and macrophages in vivo (10, 11) , suggested that GM-CSF administration might be useful clinically in situations in which the number and/or functional capacity of leukocytes is suboptimal. Initial results in cancer patients undergoing intensive therapy (12) , acquired immunodeficiency syndrome (AIDS) patients (13) , and patients with myelodysplasia (14) have been very encouraging. However, as part of the evaluation of such applications of GM-CSF therapy, it would be important to identify any other effects that GM-CSF might have on various types of normal or malignant cells of nonhemopoietic origin.
It has recently been shown that the process of bone resorption and remodeling is substantially affected by cytokines released by hemopoietic cells. Since these responses involve both osteoclasts and osteoblasts, their separate responses to growth factors are of interest. Interleukin 1 (15) and tumor necrosis factor (16) both stimulate bone resorption. The effect of hemopoietic growth factors on proliferation and differentiation of osteoblasts has, however, not been investigated, although interleukin 1 has been shown to inhibit the proliferation of mouse osteoblast-like cells (17) . Since osteoblasts respond to mitogens present in serum, we used a defined serum-free but supportive medium to examine the effect of various cytokines on a human osteogenic sarcoma cell line (MG-63) (18) . We report here that the proliferation of these human osteogenic sarcoma cells can be stimulated by highly purified recombinant human GM-CSF, and that this response can also be demonstrated in other human cells of nonhemopoietic origin. [3H]Thymidine incorporation was measured after 20 hr at 370C. The cells were detached with 10 mM EDTA and harvested onto glass-fiber cellulose discs with a cell harvester (Skatron, Lierbyen, Norway). The discs were allowed to dry and the radioactivity was determined by liquid scintillation counting. 3H dpm shown are those obtained after subtracting the dpm obtained in serum-free medium controls. For cell number measurements, cells were plated into 24-well flatbottomed tissue culture plates at a cell density of 105 cells per well. Cell numbers were determined by detaching the cells with EDTA (5 mM) and counting on a Coulter Counter.
MATERIALS AND METHODS
Human Marrow Cultures. Normal marrow aspirates were obtained with informed consent from individuals undergoing marrow harvesting for either autologous or allogeneic bone marrow transplantation. Fibroblast precursor colonyforming cell assays were performed essentially as described (23) Two other preparations of highly purified recombinant human GM-CSF were found to be similarly active on MG-63 cells ( Table 1 ). The specificity of the stimulatory effect of both GM-CSF preparations was confirmed by using a neutralizing anti-human GM-CSF monoclonal antibody. As shown in Table 1 , addition of sufficient antibody completely neutralized the ability of highly purified recombinant GM-CSF to stimulate MG-63 cells (Exp. 1, group e). However, this neutralizing effect was reversed by the addition of excess antigen-i.e., excess GM-CSF (group f), indicating that the action of the antibody preparation used in these experiments was due to its reactivity with human GM-CSF. Since small amounts of endotoxin were detected in one of the GM-CSF preparations, we also tested whether the presence of endotoxin might mimic the GM-CSF effect observed on MG-63 cells. As shown in Table 1 , endotoxin did not stimulate the proliferation of these cells. To determine whether the stimulation of cell proliferation by GM-CSF was a response unique to MG-63 cells, several other human cell types were examined under the same serum-free conditions and [3H]thymidine incorporation end point. These experiments revealed that GM-CSF could also stimulate HOS cells, an osteosarcoma cell line (21), MCF-7 breast carcinoma cells (22) , and CFU-ST clone 16 cells, a recently isolated and cloned line of simian virus 40-transformed marrow stromal cells (19) , all in a similar dose-dependent manner ( Fig. 1 and Table 2 ). The response of MCF-7 cells was also reproduced with a different GM-CSF preparation (from Genzyme) and the results were confirmed by using viable cell counts as the end point (data not shown). Anti GM-CSF antibody was added directly (control) or preincubated with the GM-CSF to be added for 2 hr at 40C prior to addition to the cells. In human marrow granulocyte-macrophage colony-forming cell assays, 20 i&g of this anti-GM-CSF antibody preparation per ml was just sufficient to completely eliminate the formation of any GM colonies in methylcellulose assays of nonadherent cells containing 1 ng of purified recombinant human GM-CSF per ml and this effect could be completely reversed by 10 ng of GM-CSF per ml. *Endotoxin standard in the Sigma endotoxin detection kit. The endotoxin content of the serum-free medium used in the assay was 0.04 ng/ml.
There was some heterogeneity in the sensitivity of the responsive cell lines to GM-CSF, and all appeared 10-20 times less sensitive than normal human granulopoietic progenitor cells tested in a colony assay (Fig. 3) Table 2 ). Thus, GM-CSF is not a general growth factor for all transformed cells. GM-CSF was also able to enhance significantly the number (by a factor of 2.4 ± 0.3; three experiments) and size of colonies derived from "fibroblast" precursors present in fresh human marrow even in the presence of 10% serum (Fig. 4) . While this latter effect could be due to an indirect mechanism (since many GM-CSF responsive hemopoietic cells are also present in these primary cultures), the fact that an immortalized derivative of these cells (CFU-ST clone 16) is also GM-CSF responsive suggests that the normal parent cell also has this capacity. Additional studies showed that the ability of GM-CSF to stimulate [3H]thymidine incorporation into MG-63 cells was independent of the presence of added albumin (0.4 mg/ml) (data not shown) or the ITS serum substitute ( 
DISCUSSION
Our findings raise a number of interesting possibilities concerning the biological role of GM-CSF and the significance of GM-CSF gene regulation. Previous studies have suggested that GM-CSF can be produced by a variety of normal cells including macrophages, T lymphocytes, fibroblasts, and endothelial cells but generally only after their activation (reviewed in ref. 25) . The data presented here suggest that responsiveness to GM-CSF is also a function of many cell types. This property can thus clearly no longer be viewed as a marker of cells derived from a hemopoietic precursor (26, 27) . GM-CSF may in fact have a broad role as a normal regulator of nonhemopoietic as well as hemopoietic cells. For example, since osteoclasts and macrophages are believed to be related (28) , GM-CSF may serve as a molecular link in the mechanisms that coordinate bone resorption by activated osteoclasts and the production of new bone by osteoblasts. GM-CSF may also be involved in the stimulation of nonhemopoietic malignant cell growth. Infiltrates of acti- as marrow stromal cells to respond to GM-CSF might also explain some of the secondary effects observed in cancer patients in which inappropriate production of GM-CSF would be a candidate mechanism of autocrine growth (for example, bone resorption in breast cancer and myelofibrosis in certain myeloproliferative diseases such as chronic myeloid leukemia). To investigate these possibilities, additional experiments will be required to establish whether the in vitro responses detected here can also be demonstrated in vivo. Such experiments will also be important to determine the potential hazards of using GM-CSF therapy in patients. In this regard, it is interesting that a recent study of transgenic GM-CSF mice indicates a number of systemic effects of continuously elevated GM-CSF production (36), which may not be due exclusively to excess macrophage numbers. 
